Hae
Aineistot 191-200 / 223
Identification of predictive ERBB mutations for targeted treatment
(Turun yliopisto, 2023-05-26)
Predictive biomarkers, such as genetic alterations, are used in personalized cancer medicine to target treatment. Genes encoding members of the ERBB family of receptor tyrosine kinases are well known to harbor genetic ...
Novel tools for identification of oncogenic driver mutations
(Turun yliopisto, 2023-02-09)
Genetic alterations contribute to the development and pathogenesis of several human cancers. These mutations accumulate in a cancer tissue over the course of time due to the instability of the cancer genome. Large-scale ...
Fusion genes in high-grade serous ovarian cancer
(Turun yliopisto, 2023-12-08)
High-grade serous ovarian cancer (HGSC) is the most common and lethal subtype of ovarian cancer. Debulking surgery is the primary treatment, supplemented by platinum and taxane combination chemotherapy. The response to ...
Function of Germline-specific Ribonucleoprotein granules-from germline to cancer
(Turun yliopisto, 2023-12-15)
Male germ cells undergo complex differentiation from embryonic germ cells, through postnatal spermatogenesis to highly specialized spermatozoa. Precise regulation of gene expression is critical for meiosis and morphological ...
Re-educating macrophages to activate antitumor immunity: One Clever Immunotherapy
(Turun yliopisto, 2023-04-14)
The immune system is our constant protector against external foes but also against our own incipient malignant cells. Unfortunately, developing cancers often learn to shut down the antitumor immune response or even to ...
The role of melanocortin-1 and -3 receptors in inflammation and atherosclerosis
(Turun yliopisto, 2023-04-28)
The melanocortin system comprises the endogenous melanocortin peptides adrenocorticotropic hormone (ACTH) and melanocyte-stimulating hormones (α-, β- & γ-MSH) as well as their five cognate receptors (MC1R – MC5R). These ...
CIP2A is a critical DNA damage response protein that drives basal-like breast cancer
(Turun yliopisto, 2023-04-14)
Basal-like breast cancer (BLBC) is an aggressive and therapeutically most challenging breast cancer subtype, due to a lack of druggable breast specific surface receptors (ER, PR, HER2) or driver mechanisms. BLBC patients ...
The Gut-pancreas axis in autoimmune diabetes
(Turun yliopisto, 2023-05-12)
The gut microbiota has been suggested to be an important factor in the development of autoimmune diseases such as type 1 diabetes (T1D). Priming of islet specific T cells in the pancreatic lymph nodes (PaLN) and their ...
Molecular surveillance of carbapenemase-producing Enterobacterales in Finland
(Turun yliopisto, 2023-04-12)
Carbapenemase-producing (CP) Enterobacterales (CPE) are a growing menace to healthcare systems worldwide. CPE infections are difficult to treat because few antimicrobials remain effective. One of the new drug combinations, ...
Antiviral modified siRNA swarms for treatment of herpes simplex virus infection
(Turun yliopisto, 2023-03-17)
Herpes simplex virus type 1 (HSV-1) is a common virus of humans carried by half of the global population. After the primary infection, HSV has the ability to establish life-long latency, wherefrom it can reactivate. The ...